Nektar Therapeutics presents positive results for NKTR-214 at AACR Annual Meeting

Nektar Therapeutics presents positive results for NKTR-214 at AACR Annual Meeting

News and Articles
Apr 8 2013

Nektar Therapeutics (Nasdaq: NKTR) today presented positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets the IL-2 receptor complex, at the 2013 American Association for Cancer Research (AACR) Annual Meeting. NKTR-214 is a new immunocytokine that is being developed as a potential treatment for multiple cancers.  NKTR-214 targets the IL-2 receptor complex through selective receptor binding to the IL2Rβ subtype.  Activation of the IL2Rβ subtype promotes tumor killing by the body's own immune system.

“We are extremely encouraged by the dramatic efficacy observed with NKTR-214 treatment in an aggressive and resistant preclinical model of melanoma,” said Stephen Doberstein , Ph.D., Senior Vice President and Chief Scientific Officer of Nektar Therapeutics.  “NKTR-214 is specifically designed to harness the potent immunostimulatory effects of the IL-2 receptor complex while minimizing the immunosuppressive effects that have greatly limited the efficacy of the native IL-2 protein.  Importantly, NKTR-214 represents the first application of our technology platform to target a receptor subtype in the tumor microenvironment while avoiding the unwanted effects from off-target receptor binding.  NKTR-214 also has improved pharmacokinetics and enhanced tumor penetration which allow for a ten-fold reduction in overall dosing.  We are excited about the potential of NKTR-214 to emerge as a powerful new immunotherapy in the fight against cancer.”

NKTR-214 is a novel immunocytokine therapy that is engineered using Nektar's polymer conjugate technology to selectively target the beneficial IL-2 receptor complex.  In the preclinical data presented at AACR, NKTR-214 exhibits differentiated IL-2 receptor binding which results in significantly altered immune cell populations in the tumor microenvironment compared to the clinically validated IL-2 protein therapy, aldesleukin.  Specifically, NKTR-214 maintains high affinity for the IL-2 receptor subunit beta, which activates tumor-killing T cells within the tumor microenvironment.  At the same time, NKTR-214 exhibits up to 100-fold reduced affinity to the IL-2 receptor subunit alpha-beta, which activates immuno-suppressive regulatory T-cells.  In a well-validated animal model of melanoma, NKTR-214 demonstrated significantly improved dosing, at once every 9 days as compared to twice a day dosing with aldesleukin.

Source:

Nektar Therapeutics

Source: www.news-medical.net

Rate article
Add a comment